Cargando…

Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease

Objectives: To explore serum zinc-α2-glycoprotein (ZAG) changes in patients with or without premature coronary artery disease (PCAD) and its association with several cardiovascular risk factors. Methods: A total of 3,364 patients who were undergone coronary angiography in Peking Union Medical Colleg...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meijuan, Zhu, Huijuan, Zhai, Tianshu, Pan, Hui, Wang, Linjie, Yang, Hongbo, Yan, Kemin, Zeng, Yong, Gong, Fengying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449697/
https://www.ncbi.nlm.nih.gov/pubmed/30984114
http://dx.doi.org/10.3389/fendo.2019.00197
_version_ 1783408904068136960
author Liu, Meijuan
Zhu, Huijuan
Zhai, Tianshu
Pan, Hui
Wang, Linjie
Yang, Hongbo
Yan, Kemin
Zeng, Yong
Gong, Fengying
author_facet Liu, Meijuan
Zhu, Huijuan
Zhai, Tianshu
Pan, Hui
Wang, Linjie
Yang, Hongbo
Yan, Kemin
Zeng, Yong
Gong, Fengying
author_sort Liu, Meijuan
collection PubMed
description Objectives: To explore serum zinc-α2-glycoprotein (ZAG) changes in patients with or without premature coronary artery disease (PCAD) and its association with several cardiovascular risk factors. Methods: A total of 3,364 patients who were undergone coronary angiography in Peking Union Medical College Hospital were screened. According to the degree of coronary artery stenosis, the number of 364 patients with PCAD (age <55 years in males and <65 years in females) and 126 age and gender matched patients without premature coronary artery disease (NPCAD) were recruited in our present study. In addition, 182 age and gender matched healthy controls were also enrolled. Serum ZAG levels were determined by enzyme-linked immunosorbent assay (ELISA) method. Results: Serum ZAG were significantly lower in the PCAD (8.03 ± 1.01 vs. 8.78 ± 1.89 μg/mL, p < 0.05) and NPCAD groups (8.28 ± 1.61 vs. 8.78 ± 1.89 μg/mL, p < 0.05), respectively, when compared with the controls. Multiple regression analysis showed that PCAD was independently associated with serum ZAG levels (B = −0.289, p = 0.002). The probability of PCAD in subjects with low tertile ZAG levels was 2.48-fold higher than those with high tertile levels after adjusting for other confounders [OR = 3.476, 95% CI 1.387–8.711, p = 0.008]. This phenomenon was more likely to be observed in male subjects with BMI <24 kg/m(2). The receiver operating curve (ROC) analysis showed a weak diagnostic performance of serum ZAG for PCAD (AUC = 0.659, 95% CI 0.612–0.705, p < 0.05). At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05). Conclusion: Serum ZAG levels were firstly found to be decreased in Chinese PCAD patients. Subjects with lower ZAG levels were more likely to have PCAD, especially for male subjects with BMI <24 kg/m(2). ZAG might be the potential diagnostic biomarkers for PCAD patients, and the combination of ZAG and clinical variables had higher discriminative performance.
format Online
Article
Text
id pubmed-6449697
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64496972019-04-12 Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease Liu, Meijuan Zhu, Huijuan Zhai, Tianshu Pan, Hui Wang, Linjie Yang, Hongbo Yan, Kemin Zeng, Yong Gong, Fengying Front Endocrinol (Lausanne) Endocrinology Objectives: To explore serum zinc-α2-glycoprotein (ZAG) changes in patients with or without premature coronary artery disease (PCAD) and its association with several cardiovascular risk factors. Methods: A total of 3,364 patients who were undergone coronary angiography in Peking Union Medical College Hospital were screened. According to the degree of coronary artery stenosis, the number of 364 patients with PCAD (age <55 years in males and <65 years in females) and 126 age and gender matched patients without premature coronary artery disease (NPCAD) were recruited in our present study. In addition, 182 age and gender matched healthy controls were also enrolled. Serum ZAG levels were determined by enzyme-linked immunosorbent assay (ELISA) method. Results: Serum ZAG were significantly lower in the PCAD (8.03 ± 1.01 vs. 8.78 ± 1.89 μg/mL, p < 0.05) and NPCAD groups (8.28 ± 1.61 vs. 8.78 ± 1.89 μg/mL, p < 0.05), respectively, when compared with the controls. Multiple regression analysis showed that PCAD was independently associated with serum ZAG levels (B = −0.289, p = 0.002). The probability of PCAD in subjects with low tertile ZAG levels was 2.48-fold higher than those with high tertile levels after adjusting for other confounders [OR = 3.476, 95% CI 1.387–8.711, p = 0.008]. This phenomenon was more likely to be observed in male subjects with BMI <24 kg/m(2). The receiver operating curve (ROC) analysis showed a weak diagnostic performance of serum ZAG for PCAD (AUC = 0.659, 95% CI 0.612–0.705, p < 0.05). At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05). Conclusion: Serum ZAG levels were firstly found to be decreased in Chinese PCAD patients. Subjects with lower ZAG levels were more likely to have PCAD, especially for male subjects with BMI <24 kg/m(2). ZAG might be the potential diagnostic biomarkers for PCAD patients, and the combination of ZAG and clinical variables had higher discriminative performance. Frontiers Media S.A. 2019-03-29 /pmc/articles/PMC6449697/ /pubmed/30984114 http://dx.doi.org/10.3389/fendo.2019.00197 Text en Copyright © 2019 Liu, Zhu, Zhai, Pan, Wang, Yang, Yan, Zeng and Gong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Liu, Meijuan
Zhu, Huijuan
Zhai, Tianshu
Pan, Hui
Wang, Linjie
Yang, Hongbo
Yan, Kemin
Zeng, Yong
Gong, Fengying
Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title_full Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title_fullStr Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title_full_unstemmed Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title_short Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease
title_sort serum zinc-α2-glycoprotein levels were decreased in patients with premature coronary artery disease
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449697/
https://www.ncbi.nlm.nih.gov/pubmed/30984114
http://dx.doi.org/10.3389/fendo.2019.00197
work_keys_str_mv AT liumeijuan serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT zhuhuijuan serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT zhaitianshu serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT panhui serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT wanglinjie serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT yanghongbo serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT yankemin serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT zengyong serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease
AT gongfengying serumzinca2glycoproteinlevelsweredecreasedinpatientswithprematurecoronaryarterydisease